human brain vascular smooth muscle cells Search Results


90
Innoprot Inc human brain vascular smooth muscle cells hbvsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Hbvsmcs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+brain+vascular+smooth+muscle+cells/Human+Brain+Vascular+Smooth+Muscle+Cells/pmc08444498-129-3-13
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells hbvsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ScienCell human brain vascular smooth muscle cells sciencell research
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Sciencell Research, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+brain+vascular+smooth+muscle+cells/human+brain+vascular+smooth+muscle+cells+sciencell+research/10__1074_slash_jbc__m110__127738-161-0-11
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells sciencell research - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ScienCell human brain vascular smooth muscle cells
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+brain+vascular+smooth+muscle+cells/human+brain+vascular+smooth+muscle+cells/pmc08673708-76-0-9
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ScienCell human brain vascular smooth muscle cells hbvsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Hbvsmcs, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+brain+vascular+smooth+muscle+cells/human+brain+vascular+smooth+muscle+cells++hbvsmcs++catalog++1100/pm40456777-346-0-7
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells hbvsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Bioarray Inc human brain vascular smooth muscle cells (hbvsmcs
ClC-2 knockdown inhibited the AngII-induced efflux of Cl − in <t>HBVSMCs.</t> a HBVSMCs were treated with angiotensin II (AngII) at different concentrations (10 − 9 , 10 − 8 10 − 7 and 10 − 6 M) for 48 h. Cell viability was determined using the CCK-8 assay. b Intracellular Cl − concentration [Cl − ] i was examined using an MEQ fluorescence probe. c The correlation between [Cl − ] i and cell viability was analyzed. d and e – The expression of ClC-2 in the cells treated as described in ( a ) was examined using western blotting ( d ) and quantitative real-time PCR ( e ). f Cells were treated with ClC-2 siRNA (20 nM) or negative siRNA for 48 h before AngII incubation (10 − 7 M) for a further 48 h. [Cl − ] i was examined. * p < 0.05, ** p < 0.01 vs. control, ## p < 0.01 vs. AngII alone, n = 6
Human Brain Vascular Smooth Muscle Cells (Hbvsmcs, supplied by Bioarray Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+brain+vascular+smooth+muscle+cells/human+brain+vascular+smooth+muscle+cells++hbvsmcs/pmc06022329-34-0-11
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells (hbvsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

N/A
Vascular smooth muscle cell is the cellular substate of most significant arterial disease. The increased growth potential of vascular smooth muscle cells represents one of the crucial anomalies responsible for the development of essential vascular
  Buy from Supplier



Image Search Results


MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Journal: Acta Neuropathologica Communications

Article Title: MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

doi: 10.1186/s40478-021-01257-9

Figure Lengend Snippet: MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Article Snippet: Primary cultures of human brain vascular smooth muscle cells (HBVSMCs) were obtained from Innoprot (Derio, Bizkaia, Spain).

Techniques: Expressing, Immunocytochemistry, Western Blot, Transfection

ClC-2 knockdown inhibited the AngII-induced efflux of Cl − in HBVSMCs. a HBVSMCs were treated with angiotensin II (AngII) at different concentrations (10 − 9 , 10 − 8 10 − 7 and 10 − 6 M) for 48 h. Cell viability was determined using the CCK-8 assay. b Intracellular Cl − concentration [Cl − ] i was examined using an MEQ fluorescence probe. c The correlation between [Cl − ] i and cell viability was analyzed. d and e – The expression of ClC-2 in the cells treated as described in ( a ) was examined using western blotting ( d ) and quantitative real-time PCR ( e ). f Cells were treated with ClC-2 siRNA (20 nM) or negative siRNA for 48 h before AngII incubation (10 − 7 M) for a further 48 h. [Cl − ] i was examined. * p < 0.05, ** p < 0.01 vs. control, ## p < 0.01 vs. AngII alone, n = 6

Journal: Cellular & Molecular Biology Letters

Article Title: ClC-2 knockdown prevents cerebrovascular remodeling via inhibition of the Wnt/β-catenin signaling pathway

doi: 10.1186/s11658-018-0095-z

Figure Lengend Snippet: ClC-2 knockdown inhibited the AngII-induced efflux of Cl − in HBVSMCs. a HBVSMCs were treated with angiotensin II (AngII) at different concentrations (10 − 9 , 10 − 8 10 − 7 and 10 − 6 M) for 48 h. Cell viability was determined using the CCK-8 assay. b Intracellular Cl − concentration [Cl − ] i was examined using an MEQ fluorescence probe. c The correlation between [Cl − ] i and cell viability was analyzed. d and e – The expression of ClC-2 in the cells treated as described in ( a ) was examined using western blotting ( d ) and quantitative real-time PCR ( e ). f Cells were treated with ClC-2 siRNA (20 nM) or negative siRNA for 48 h before AngII incubation (10 − 7 M) for a further 48 h. [Cl − ] i was examined. * p < 0.05, ** p < 0.01 vs. control, ## p < 0.01 vs. AngII alone, n = 6

Article Snippet: Human brain vascular smooth muscle cells (HBVSMCs) were purchased from Creative Bioarray (CSC-7824 W, NY, USA) and cultured in SuperCult Smooth Muscle Cell Medium (Creative Bioarray) containing 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin in a humidified incubator with 5% CO 2 and 95% O 2 at 37 °C.

Techniques: CCK-8 Assay, Concentration Assay, Fluorescence, Expressing, Western Blot, Real-time Polymerase Chain Reaction, Incubation

ClC-2 downregulation prevented AngII-induced HBVSMC migration and invasion. a HBVSMCs transfected with ClC-2 siRNA (siClC-2; 20 nM) or negative siRNA (negative; 20 nM) were subjected to angiotensin II (AngII) treatment (10 − 7 M). The wound healing assay was performed. Representative images are shown (× 100). b The quantification results for the wound closure. c HBVSMC migration was examined via transwell analysis. Representative images are shown (× 100). d The columns represent the relative numbers of invasive cells. ** p < 0.01 vs. control, ## p < 0.01 vs. AngII alone, n = 6

Journal: Cellular & Molecular Biology Letters

Article Title: ClC-2 knockdown prevents cerebrovascular remodeling via inhibition of the Wnt/β-catenin signaling pathway

doi: 10.1186/s11658-018-0095-z

Figure Lengend Snippet: ClC-2 downregulation prevented AngII-induced HBVSMC migration and invasion. a HBVSMCs transfected with ClC-2 siRNA (siClC-2; 20 nM) or negative siRNA (negative; 20 nM) were subjected to angiotensin II (AngII) treatment (10 − 7 M). The wound healing assay was performed. Representative images are shown (× 100). b The quantification results for the wound closure. c HBVSMC migration was examined via transwell analysis. Representative images are shown (× 100). d The columns represent the relative numbers of invasive cells. ** p < 0.01 vs. control, ## p < 0.01 vs. AngII alone, n = 6

Article Snippet: Human brain vascular smooth muscle cells (HBVSMCs) were purchased from Creative Bioarray (CSC-7824 W, NY, USA) and cultured in SuperCult Smooth Muscle Cell Medium (Creative Bioarray) containing 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin in a humidified incubator with 5% CO 2 and 95% O 2 at 37 °C.

Techniques: Migration, Transfection, Wound Healing Assay

ClC-2 inhibition attenuated the AngII-induced activation of Wnt/β-catenin signaling. a through f HBVSMCs were transfected with ClC-2 siRNA (siClC-2; 20 nM) or negative siRNA (negative; 20 nM) and then stimulated with angiotensin II (AngII; 10 − 7 M) for 48 h. Shown are the western blotting results for β-catenin phosphorylation ( a ), β-catenin cytosol ( b ) and nuclear protein ( c ) levels, GSK-3β phosphorylation ( d ), and survivin ( e ) and cyclin D1 ( f ) protein expression. g Quantitative real-time PCR analysis of Wnt3a and Wnt5a mRNA expression. h The cells were treated with recombinant Wnt3a (100 ng/ml) for 48 h. Wnt3a expression was examined using quantitative real-time. i Viability of HBVSMCs transfected with ClC-2 siRNA followed by co-incubation with recombinant Wnt3a and AngII. ** p < 0.01 vs. control, ## p < 0.01 vs. AngII alone, $$ p < 0.01 vs. AngII+siClC-2, n = 4

Journal: Cellular & Molecular Biology Letters

Article Title: ClC-2 knockdown prevents cerebrovascular remodeling via inhibition of the Wnt/β-catenin signaling pathway

doi: 10.1186/s11658-018-0095-z

Figure Lengend Snippet: ClC-2 inhibition attenuated the AngII-induced activation of Wnt/β-catenin signaling. a through f HBVSMCs were transfected with ClC-2 siRNA (siClC-2; 20 nM) or negative siRNA (negative; 20 nM) and then stimulated with angiotensin II (AngII; 10 − 7 M) for 48 h. Shown are the western blotting results for β-catenin phosphorylation ( a ), β-catenin cytosol ( b ) and nuclear protein ( c ) levels, GSK-3β phosphorylation ( d ), and survivin ( e ) and cyclin D1 ( f ) protein expression. g Quantitative real-time PCR analysis of Wnt3a and Wnt5a mRNA expression. h The cells were treated with recombinant Wnt3a (100 ng/ml) for 48 h. Wnt3a expression was examined using quantitative real-time. i Viability of HBVSMCs transfected with ClC-2 siRNA followed by co-incubation with recombinant Wnt3a and AngII. ** p < 0.01 vs. control, ## p < 0.01 vs. AngII alone, $$ p < 0.01 vs. AngII+siClC-2, n = 4

Article Snippet: Human brain vascular smooth muscle cells (HBVSMCs) were purchased from Creative Bioarray (CSC-7824 W, NY, USA) and cultured in SuperCult Smooth Muscle Cell Medium (Creative Bioarray) containing 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin in a humidified incubator with 5% CO 2 and 95% O 2 at 37 °C.

Techniques: Inhibition, Activation Assay, Transfection, Western Blot, Expressing, Real-time Polymerase Chain Reaction, Recombinant, Incubation